Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGNNASDAQ:LYRANASDAQ:OSRHNASDAQ:QTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$2.48-22.2%$2.28$1.55▼$5.60$28.35M1.2442,179 shs176,659 shsLYRALyra Therapeutics$20.48+315.4%$5.20$3.81▼$36.73$27.14M0.04121,402 shs26.43 million shsOSRHOSR$1.32-9.0%$1.48$1.02▼$13.40$25.45M1.542.92 million shs119,667 shsQTIQT Imaging$0.81+2.9%$0.71$0.35▼$0.86$22.07M-0.2158,380 shs53,856 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies0.00%+62.18%+46.26%-7.94%-44.16%LYRALyra Therapeutics0.00%+1.96%-13.57%-51.85%-71.46%OSRHOSR0.00%+16.29%-4.33%-48.12%+134,899,900.00%QTIQT Imaging0.00%-1.42%+8.44%+74.72%+12.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLGNCollPlant Biotechnologies2.3596 of 5 stars3.73.00.00.03.00.00.6LYRALyra Therapeutics2.7738 of 5 stars3.24.00.00.03.31.70.6OSRHOSRN/AN/AN/AN/AN/AN/AN/AN/AQTIQT ImagingN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 3.33Buy$11.50364.65% UpsideLYRALyra Therapeutics 2.33Hold$100.00388.31% UpsideOSRHOSR 0.00N/AN/AN/AQTIQT Imaging 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LYRA, QTI, OSRH, and CLGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.003/27/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/14/2025LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$100.00 ➝ $100.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$2.47M11.47N/AN/A$2.47 per share1.00LYRALyra Therapeutics$1.19M22.90N/AN/A$1.56 per share13.13OSRHOSR-$148.95K-170.83N/AN/AN/A∞QTIQT Imaging$4.00M5.52N/AN/A($1.91) per share-0.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$7.02M-$1.22N/AN/AN/A-2,680.00%-77.05%-61.43%6/4/2025 (Estimated)LYRALyra Therapeutics-$62.68M-$60.50N/AN/AN/A-6,635.76%-125.07%-59.74%8/12/2025 (Estimated)OSRHOSRN/AN/A0.00∞N/AN/AN/AN/AN/AQTIQT Imaging-$4.03MN/A0.00∞N/AN/AN/A-65.94%8/6/2025 (Estimated)Latest LYRA, QTI, OSRH, and CLGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2025Q1 2025CLGNCollPlant Biotechnologies-$0.37-$0.13+$0.24-$0.13$9.76 million$2.06 million5/20/2025Q1 2025OSRHOSRN/A-$1.04N/A-$1.04N/A$0.76 million5/6/2025Q1 2025LYRALyra Therapeutics-$7.50-$6.00+$1.50-$0.13$0.16 million$0.18 million3/26/2025Q4 2024CLGNCollPlant Biotechnologies-$0.42-$0.34+$0.08-$0.34$0.36 million$0.17 million3/13/2025Q4 2024LYRALyra Therapeutics-$6.00-$8.00-$2.00-$0.16$0.21 million$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/AQTIQT ImagingN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A5.385.23LYRALyra TherapeuticsN/A3.643.64OSRHOSRN/AN/AN/AQTIQT ImagingN/A1.060.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%LYRALyra Therapeutics95.62%OSRHOSR55.30%QTIQT Imaging24.19%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%LYRALyra Therapeutics3.25%OSRHOSR33.67%QTIQT Imaging75.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7011.46 million10.36 millionOptionableLYRALyra Therapeutics501.33 million62.39 millionOptionableOSRHOSRN/A19.28 million2.68 millionN/AQTIQT ImagingN/A27.13 million6.68 millionN/ALYRA, QTI, OSRH, and CLGN HeadlinesRecent News About These CompaniesQT Imaging (NASDAQ:QTI) Stock Price Down 2.9% - Here's WhyMay 28, 2025 | americanbankingnews.comLadenburg Thalmann Initiates Coverage of QT Imaging Holdings (QTIH) with Buy RecommendationMay 20, 2025 | msn.comQT Imaging Holdings Delivers Its Breast Imaging Scanner to Innovative Radiology in Des Moines, IowaMay 15, 2025 | finance.yahoo.comQT Imaging Holdings Announces $200,000 PIPE InvestmentMay 14, 2025 | joplinglobe.comQT Imaging Announces First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comQT Imaging Approves Executive Stock Options PlanApril 23, 2025 | tipranks.comQT Imaging Holdings Announces $500,000 Insiders PIPE InvestmentApril 10, 2025 | businesswire.comQT Imaging Holdings Announces $500,000 Insiders PIPE InvestmentApril 10, 2025 | businesswire.comQT Imaging Holdings to Participate in the 2025 SBI Breast Imaging SymposiumApril 8, 2025 | businesswire.comQT Imaging Announces Fourth Quarter and Full Year 2024 Financial Results and Provides 2025/26 OutlookApril 2, 2025 | seekingalpha.comQT Imaging Holdings Announces Shipment of Six QT Breast Acoustic CT Scanners in the First Quarter of 2025April 1, 2025 | businesswire.comQT Imaging Holdings Receives $10.1 Million in New Funding to Support Working Capital and Retire DebtFebruary 27, 2025 | businesswire.comQTI Stock Earnings: QT Imaging Holdings Reported Results for Q2 2024February 14, 2025 | investorplace.comQT Imaging Holdings Inc. secures sublease agreementJanuary 24, 2025 | msn.comQT Imaging Holdings Introduces Machine Learning-Enabled Image Interpolation Algorithm to Substantially Reduce Scan TimeJanuary 15, 2025 | joplinglobe.comQT Imaging Holdings Announces Clearing of All Its Short-Term Liabilities and Forecasts Solid Revenue GrowthJanuary 13, 2025 | finance.yahoo.comQT Imaging Holdings Announces New Commercial Shipment in Partnership with Couri CenterDecember 12, 2024 | finance.yahoo.comQT Imaging Holdings to Attend Radiological Society of North America 2024 Annual MeetingNovember 21, 2024 | finance.yahoo.comQT Imaging Holdings, Inc. (NASDAQ:QTI) Director Acquires $248,287.56 in StockNovember 15, 2024 | insidertrades.comQTI Stock Earnings: QT Imaging Holdings Reported Results for Q2 2024November 15, 2024 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLYRA, QTI, OSRH, and CLGN Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$2.48 -0.71 (-22.17%) Closing price 03:59 PM EasternExtended Trading$2.11 -0.37 (-14.75%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.Lyra Therapeutics NASDAQ:LYRA$20.48 +15.55 (+315.40%) Closing price 03:59 PM EasternExtended Trading$19.04 -1.44 (-7.03%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.OSR NASDAQ:OSRH$1.32 -0.13 (-8.97%) As of 03:57 PM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.QT Imaging NASDAQ:QTI$0.81 +0.02 (+2.95%) As of 05/30/2025QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems for detection, diagnosis, monitoring, and treatment of diseases. The company offers QT Ultrasound Breast Scanner, an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient's breast. QT Imaging Holdings, Inc. was founded in 2011 and is based in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
